Baseline and change from baseline in tumor burden compared with patient outcomes.

Abstract

e17530 Background: The impact of baseline tumor burden (bTB) and percentage reduction in tumor burden (dTB) on patient outcome has not been systematically studied in oncology clinical trials. We assess the relationship between both bTB and dTB and objective response (OR), progression free and overall survival (PFS and OS) in bevacizumab (B) and trastuzumab… (More)

Topics

Cite this paper

@article{Kaiser2009BaselineAC, title={Baseline and change from baseline in tumor burden compared with patient outcomes.}, author={L Kaiser and Jane Fridlyand and Gwendolyn A Fyfe}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2009}, volume={27 15_suppl}, pages={e17530} }